Bluejay Diagnostics annual stock-based compensation
2020
2021
2022
2023
2024
2025
Bluejay Diagnostics Stock-Based Compensation Growth & History (BJDX)
Bluejay Diagnostics's stock-based compensation was $6 for fiscal 2025.
View full Bluejay Diagnostics company overviewBluejay Diagnostics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $6 | −$20,088 | −99.97% |
| 2024 | 2024-12-31 | $20,094 | −$169,151 | −89.38% |
| 2023 | 2023-12-31 | $189,245 | −$243,759 | −56.29% |
| 2022 | 2022-12-31 | $433,004 | $364,546 | +532.51% |
| 2021 | 2021-12-31 | $68,458 | $64,728 | +1735.34% |
| 2020 | 2020-12-31 | $3,730 | — | — |
Bluejay Diagnostics quarterly stock-based compensation
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $0 | $1,563 | — |
| Q1 2026 | 2026-03-31 | $0 | −$1,312 | — |
| Q4 2025 | 2025-12-31 | $74 | — | — |
| Q3 2025 | 2025-09-30 | $183 | −$4,609 | −96.18% |
| Q2 2025 | 2025-06-30 | −$1,563 | −$7,573 | — |
| Q1 2025 | 2025-03-31 | $1,312 | −$10,562 | −88.95% |
| Q3 2024 | 2024-09-30 | $4,792 | $47,274 | — |
| Q2 2024 | 2024-06-30 | $6,010 | −$21,694 | −78.31% |
| Q1 2024 | 2024-03-31 | $11,874 | −$207,715 | −94.59% |
| Q3 2023 | 2023-09-30 | −$42,482 | −$155,701 | — |
| Q2 2023 | 2023-06-30 | $27,704 | −$78,410 | −73.89% |
| Q1 2023 | 2023-03-31 | $219,589 | $93,503 | +74.16% |
| Q4 2022 | 2022-12-31 | $87,585 | $65,950 | +304.83% |
| Q3 2022 | 2022-09-30 | $113,219 | $66,715 | +143.46% |
| Q2 2022 | 2022-06-30 | $106,114 | $105,959 | +68360.65% |
| Q1 2022 | 2022-03-31 | $126,086 | $125,922 | +76781.71% |
| Q4 2021 | 2021-12-31 | $21,635 | — | — |
| Q3 2021 | 2021-09-30 | $46,504 | $40,253 | +643.94% |
| Q2 2021 | 2021-06-30 | $155 | −$524 | −77.17% |
| Q1 2021 | 2021-03-31 | $164 | $2,684 | — |
| Q3 2020 | 2020-09-30 | $6,251 | — | — |
| Q2 2020 | 2020-06-30 | $679 | — | — |
| Q1 2020 | 2020-03-31 | −$2,520 | — | — |
Bluejay Diagnostics stock-based compensation trends
Over the last five fiscal years, Bluejay Diagnostics's stock-based compensation decreased from $3,730 to $6, a change of −$3,724. The latest reported quarter, Q2 2026, shows $0.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Bluejay Diagnostics source filings ↗